Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie glejak mózgu (typ IDH wild-type, MGMT zmetylowany), który przeszedł operację lub biopsję
- •Zmienne widoczne na badaniu obrazowym (MRI/CT) o rozmiarze co najmniej 10 mm
- •Wcześniejsze leczenie chemioterapią (temozolomid) i radioterapią
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala Karnofskiego ≥60%)
- •Prawidłowe wyniki badań krwi (wystarczająca liczba białych i czerwonych krwinek, płytek)
- •Prawidłowe funkcje wątroby i nerek
- •Pacjenci z HIV na leczeniu mogą uczestniczyć, jeśli wirus jest niedetektowalny
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (36)
Mayo Clinic Hospital in Arizona
Phoenix, United States
City of Hope Comprehensive Cancer Center
Duarte, United States
UC San Diego Moores Cancer Center
La Jolla, United States
Keck Medicine of USC Koreatown
Los Angeles, United States
Los Angeles General Medical Center
Los Angeles, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
UCHealth University of Colorado Hospital
Aurora, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
Mayo Clinic in Florida
Jacksonville, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
Moffitt Cancer Center
Tampa, United States
Emory University Hospital Midtown
Atlanta, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
University of Chicago Medicine-Orland Park
Orland Park, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
Mayo Clinic in Rochester
Rochester, United States
Saint Barnabas Medical Center
Livingston, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Rutgers New Jersey Medical School
Newark, United States
Roswell Park Cancer Institute
Buffalo, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, United States
Wake Forest University Health Sciences
Winston-Salem, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, United States
University of Virginia Cancer Center
Charlottesville, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, United States
Trial contact
Alyx B. Porter Umphrey
Alyx B. Porter Umphrey
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jana L. Portnow
PRINCIPAL_INVESTIGATOR
Site Public Contact
David E. Piccioni
PRINCIPAL_INVESTIGATOR
Site Public Contact
Orwa Aboud
PRINCIPAL_INVESTIGATOR
Site Public Contact
Denise M. Damek
PRINCIPAL_INVESTIGATOR
Site Public Contact
Macarena I. De La Fuente
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sani H. Kizilbash
PRINCIPAL_INVESTIGATOR
Site Public Contact
Patrick T. Grogan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kimberly Hoang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Steven J. Chmura
PRINCIPAL_INVESTIGATOR
Site Public Contact
John L. Villano
PRINCIPAL_INVESTIGATOR
Site Public Contact
Vincent Yeung
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Jose R. McFaline Figueroa
PRINCIPAL_INVESTIGATOR
Site Public Contact
Roy E. Strowd
PRINCIPAL_INVESTIGATOR
Site Public Contact
Lalanthica V. Yogendran
PRINCIPAL_INVESTIGATOR
Site Public Contact
Pierre Giglio
PRINCIPAL_INVESTIGATOR
Site Public Contact
James D. Battiste
PRINCIPAL_INVESTIGATOR
Site Public Contact
Megan Mantica
PRINCIPAL_INVESTIGATOR
Site Public Contact
Mariza Daras
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ankush Bhatia
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.